

Request Information

Proteoglycan Mimetics For Enhanced Wound Healing Angiogenesis And Vascular Repair

Tech ID: 29598 / UC Case 2018-492-0

ABSTRACT

Researchers at the University of California, Davis We have developed proteoglycan mimetics that alters the extracellular environment to promote local vascular repair and wound healing.

FULL DESCRIPTION

Current therapies for treating wounds and ischemia often use growth factors, such as vascular endothelial growth factor (VEGF) and stents promote revascularization and blood vessel growth and prevent closure of a blood vessel. The clinical success of such growth factor therapies for wounds, however, have been limited dude to overexpression of matrix metalloproteases (MMPs) after injury which can degrade and inactivate the growth factors. Additionally, while stents provide structural support and are effective in preventing artery closure short term, they are ineffective in preventing restenosis (even with the introduction of drug-eluting stents (DESs)) long term.

Researchers at the University of California, Davis We have developed proteoglycan mimetics that alter the extracellular environment to promote local vascular repair and wound healing without the use of stents. This method utilizes a combination of collagen-binding and integrin-binding peptides and a glycan to target and enhance endothelial cell and endothelial progenitor cell capture. The pro-angiogenic scaffold supports tissue regeneration while limiting systemic exposure to VEGF, suppressing platelet binding and inflammation while promoting reendothelialization. These mimetics can potentially prevent rapid collagen matrix degradation and accelerate ischemic wound healing while preventing long-term complications including thrombosis, scaring and a foreign body response. removing the need for stents.

APPLICATIONS

- ► Tissue regeneration
- ► Atherosclerotic conditions
- ► Enhanced wound healing and vascular repair

FEATURES/BENEFITS

- ▶ Pro-angiogenic scaffold
- ► Accelerates ischemic wound healing
- ▶ Prevents rapid collagen matrix degradation
- ▶ Limits systematic exposure to VEGF
- ► Can be delivered via catheter post balloon angioplasty

PATENT STATUS

Country Type Number Dated Case

CONTACT

Raj Gururajan rgururajan@ucdavis.edu tel: 530-754-7637.



INVENTORS

- ▶ Lam, Kit S.
- Liu, Ruiwu
- ▶ Wang, Aijun

OTHER INFORMATION

KEYWORDS

collagen-binding,
integrin-binding,
peptidoglycans,
proteoglycan mimetics,
matrix metalloproteases,
MMPs, restenosis, stent,
drug-eluting stents, DES,
pro-angiogenic scaffold,
tissue regeneration,
VEGF,
reendothelialization,
endothelial cell,
endothelial progenitor,
cell capture, collagen
matrix degradation,

wound healing, ischemic

 United States Of America
 Issued Patent
 11,612,663
 03/28/2023
 2018-492

 United States Of America
 Published Application
 20230346960
 11/02/2023
 2018-492

CATEGORIZED AS

- Medical
 - Devices
 - Disease:

Cardiovascular and

Circulatory System

- ▶ Other
- ▶ Therapeutics

RELATED CASES

2018-492-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ Novel Solid Tumor Chemodrug LLS2
- ▶ Affinity Peptides for Diagnosis and Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 and Zika Virus Infections
- ▶ Nanoparticles for Drug Delivery, Tissue Targeting and Imaging Analysis
- ► Conjugates That Combine HDAC Inhibitors and Retinoids into Disease Preventatives/Treatments
- ► Artificial Intelligence-Based Evaluation Of Drug Efficacy
- ▶ A Novel RGD-Containing Cyclic Peptide for use in Cancer Imaging and as a Targeted-Therapy Ligand
- ► Site-Specific Ligation and Compound Conjugation to Existing Antibodies
- ► Ligands for Alpha-4-Beta-1 Integrin
- Exosome-Mimicking Nanovesicles
- ► Functional Illumination in Living Cells
- ► Multifunctional Porphyrin-Based Nanomedicine Platform
- ▶ Engineered Biomaterial to Prevent Endothelial Inflammation
- ► Early Detection of Ovarian Cancer Using Markers to Short Chain Carbohydrates
- ▶ PVA Nanocarrier System for Controlled Drug Delivery
- Systems and Methods of Single-Cell Segmentation and Spatial Multiomics Analyses

University of California, Davis
Technology Transfer Office

1 Shields Avenue, Mrak Hall 4th Floor,
Davis, CA 95616

Tel:

© 2018 - 2023, The Regents of the University of

530.754.8649

California

techtransfer@ucdavis.edu

Terms of use

https://research.ucdavis.edu/technology-

Privacy Notice

<u>transfer/</u>

Fax:

530.754.7620